Hedera Dx Announces Publication of International, Multicenter, Pan-Cancer Liquid Biopsy Test Panel Analytical Validation in medRxiv
October 28, 2024
Lausanne, Switzerland (October 28th, 2024). Hedera Dx, an oncology company specializing in liquid biopsies and real-world data (RWD), announces the publication of an analytical validation for a pan-cancer NGS liquid biopsy solution based on a unique decentralized and international multicenter study.
- Hedera Dx's pan-cancer liquid biopsy solution, Hedera Profiling 2 ctDNA test panel (HP2), has demonstrated exceptional performance in an international multicenter analytical performance evaluation.
- This validation paves the way for the widespread adoption of liquid biopsy in hospitals, enabling more rapid and personalized cancer care.
- The study, involving 10+ expert centers from 8 countries, highlights the power of global collaboration in advancing liquid biopsy technology.
HP2, a hybrid capture-based NGS assay, has been rigorously tested in a comprehensive study involving multiple expert cancer centers across the globe. The results demonstrate exceptional performance in detecting a wide range of genomic alterations, including single nucleotide variants (SNVs), insertions and deletions (Indels), copy number variations (CNVs), fusions, and microsatellite instability (MSI) in circulating tumor DNA (ctDNA).
“The validation of Hedera Dx's HP2 test represents a significant advancement in the field of liquid biopsy, particularly for its potential to inform the rapid selection of targeted cancer therapies in daily practice. I am impressed by the test’s ability to detect a wide range of genomic alterations in circulating tumor DNA, including gene fusions and MSI which are exciting emerging applications for liquid biopsy use.” said Léa Payen-Gay, Professor at Hospices Civils de Lyon.
This validation is a major milestone for Hedera Dx and also for the field of in-house liquid biopsy testing.
"We are thrilled to share the results of this important study," said Damien Lapray, CCO at Hedera Dx. "The validation of HP2 demonstrates its potential to transform the way cancer is diagnosed at a molecular level and treated. We are committed to making this innovative technology accessible to patients and healthcare providers worldwide."
The study, which involved collaboration from 10+ centers in 8 countries, highlights the power of international collaboration in advancing liquid biopsy research. By pooling resources and expertise, researchers were able to conduct a comprehensive evaluation of HP2's performance across a diverse set of clinical samples.
The publication of this study in medRxiv marks a significant step forward in the development of liquid biopsy technology. Hedera Dx is now working towards commercialization of the HP2 test.
###
For additional information:
Tommi Lehtonen, CEO
Hedera Dx
+41 21 561 35 45
tlehtonen@hederadx.com
Damien Lapray, CCO
Hedera Dx
+41 21 561 35 45
dlapray@hederadx.com
About Hedera Profiling 2 ctDNA test panel
The Hedera Profiling 2 ctDNA Test Panel* is at the forefront of clinical actionability, providing a compact, yet comprehensive 32-gene assay optimized to run ctDNA samples with NGS technologies commonly used in routine by hospital laboratories. The panel enables simultaneous detection of Single Nucleotide Variants (SNVs), Insertions and Deletions (Indels), Copy Number Variations (CNVs), Fusions, and Microsatellite Instability (MSI) across more than ten common solid tumor types in a single DNA-only liquid biopsy assay.
Seamlessly integrating into routine hospital laboratories NGS workflows, precise results can be obtained within a swift 5 calendar days, utilizing just 10 ng of cell-free DNA and empowering laboratories to expedite testing timelines without compromising on data accuracy with an overall panel sensitivity > 97% and specificity > 99% at 0.5% VAF for clinically relevant variants classified ESCAT Level I across multiple cancer types in the guidelines.
Each kit includes all the reagents for cfDNA extraction, library preparation and target enrichment, as well as the software, Hedera PrimeTM, required to analyze sequencing data and generate customizable reports within a few clicks with suggestions of cancer therapy options.
* For performance studies only, not authorized for diagnostic procedures until its clinical performance has been established by the user and all local regulatory requirements for routine testing are met. Not available in all countries including the United States.
About Hedera Dx
Founded in Switzerland in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, Hedera Dx aims to revolutionize cancer care through the global adoption of liquid biopsies. The company specializes on next-generation sequencing (NGS) technology and fit-for-purpose, large-scale real-world data (RWD) to enhance cancer patient outcomes. Their AI-driven platform, Hedera Frame, powered by the CE IVDR certified medical device, Hedera PrimeTM, provides scalable solutions for the aggregation and analysis of clinicogenomics data. Hedera Dx supports healthcare professionals, including molecular pathologists and oncologists, in accelerating the adoption of precision oncology.